StockWatch
·

Alamar Biosciences, Inc. Q3 FY26 Results

ALMRQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue33.5514.0%68.5%
Total Income33.5514.0%68.5%
Expenditure48.6813.3%75.1%
PBT-13.250.3%75.3%
Net Profit-13.341.1%66.8%
OPM-45.13%0.85pp5.53pp
NPM-39.77%5.08pp0.41pp
EPS-0.1913.6%72.5%
View full financials

Alamar Biosciences Reports Q3 2026 Financial Results and Raises 2026 Revenue Guidance

04 Nov 2026 · 4 Nov, 2:44 am

Summary

Alamar Biosciences reported strong third quarter 2026 financial results, with total revenue reaching $33.5 million, a significant 68% increase year-over-year. The company also raised its full-year 2026 revenue guidance to a range of $121 million to $123 million, projecting 64% growth at the midpoint. This performance was driven by robust growth across instrument, consumable, and services revenue streams, with gross margin improving to 61.5%. Management highlighted continued strong demand for their platform and strategic collaborations as key drivers.

Key Highlights

  1. 1

    Alamar Biosciences reported $33.5 million of total revenue for the third quarter of 2026, an increase of 68% compared to the corresponding period of 2025.

  2. 2

    The company is raising its full-year 2026 revenue guidance to $121 million to $123 million, representing growth of 64% at the midpoint of the range as compared to 2025.

  3. 3

    Instrument revenue grew 50% to $8.5 million for Q3 2026, driven by continued growth in new instrument placements.

  4. 4

    Consumable revenue increased 79% to $17.8 million for Q3 2026, driven by strong demand for multiplex panels.

  5. 5

    Services and other revenue grew 69% to $7.2 million for Q3 2026, driven by strong demand for custom assay development services.

  6. 6

    Gross margin was 61.5% for the third quarter of 2026, an improvement from 59.7% for the corresponding prior-year period.

Management Comments

Y

Yuling Luo

Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time. Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale. Tod has been an outstanding partner and leader during a pivotal period for Alamar. He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.

T

Tod White

It has been a privilege to work alongside this exceptional team. Their talent, dedication, and belief in what precision proteomics can do to improve human health have driven everything we have accomplished. Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.

Informational and educational content only. Not investment advice.